Johnson & Johnson (NYSE:JNJ)‘s stock had its “neutral” rating reiterated by research analysts at Credit Suisse Group AG in a report released on Monday. They currently have a $123.00 price target on the stock. Credit Suisse Group AG’s price target would suggest a potential upside of 4.54% from the stock’s current price.
Other research analysts have also issued research reports about the company. Wells Fargo & Co. reaffirmed a “buy” rating on shares of Johnson & Johnson in a report on Monday, June 6th. Leerink Swann reaffirmed a “buy” rating on shares of Johnson & Johnson in a report on Sunday, May 22nd. Zacks Investment Research raised Johnson & Johnson from a “hold” rating to a “buy” rating and set a $139.00 target price for the company in a report on Friday, August 5th. Deutsche Bank AG reaffirmed a “buy” rating and set a $142.00 target price on shares of Johnson & Johnson in a report on Friday, August 19th. Finally, Vetr raised Johnson & Johnson from a “hold” rating to a “buy” rating and set a $124.21 price objective for the company in a report on Monday, August 22nd. One investment analyst has rated the stock with a sell rating, eleven have given a hold rating and twelve have issued a buy rating to the stock. The company has an average rating of “Hold” and an average target price of $119.57.
Johnson & Johnson (NYSE:JNJ) traded down 0.50% during mid-day trading on Monday, reaching $117.66. 5,457,633 shares of the company’s stock were exchanged. The stock has a 50-day moving average of $120.64 and a 200-day moving average of $116.04. Johnson & Johnson has a one year low of $89.90 and a one year high of $126.07. The stock has a market cap of $321.90 billion, a price-to-earnings ratio of 21.93 and a beta of 0.61.
Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Tuesday, July 19th. The company reported $1.74 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.68 by $0.06. The business earned $18.50 billion during the quarter, compared to analyst estimates of $17.98 billion. Johnson & Johnson had a return on equity of 24.70% and a net margin of 20.97%. On average, equities research analysts anticipate that Johnson & Johnson will post $6.69 earnings per share for the current year.
The business also recently announced a quarterly dividend, which was paid on Tuesday, September 6th. Stockholders of record on Tuesday, August 23rd were paid a $0.80 dividend. The ex-dividend date was Friday, August 19th. This represents a $3.20 dividend on an annualized basis and a dividend yield of 2.72%. Johnson & Johnson’s dividend payout ratio is currently 60.15%.
In other news, VP Dominic J. Caruso sold 41,146 shares of the stock in a transaction on Tuesday, July 26th. The stock was sold at an average price of $125.01, for a total value of $5,143,661.46. Following the sale, the vice president now directly owns 157,819 shares of the company’s stock, valued at $19,728,953.19. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CAO Ronald A. Kapusta sold 2,935 shares of the stock in a transaction on Friday, July 22nd. The stock was sold at an average price of $125.01, for a total value of $366,904.35. Following the completion of the sale, the chief accounting officer now directly owns 28,660 shares in the company, valued at $3,582,786.60. The disclosure for this sale can be found here. 0.11% of the stock is owned by insiders.
Large investors have recently added to or reduced their stakes in the company. J.P. Marvel Investment Advisors LLC acquired a new position in shares of Johnson & Johnson during the fourth quarter worth about $8,650,000. Laurel Wealth Advisors Inc. acquired a new position in shares of Johnson & Johnson during the fourth quarter worth about $4,950,000. Norges Bank acquired a new position in shares of Johnson & Johnson during the fourth quarter worth about $2,532,680,000. TRUE Private Wealth Advisors acquired a new position in shares of Johnson & Johnson during the fourth quarter worth about $1,207,000. Finally, Investment Counsel Inc. acquired a new position in shares of Johnson & Johnson during the fourth quarter worth about $4,078,000. 65.31% of the stock is currently owned by hedge funds and other institutional investors.
Johnson & Johnson Company Profile
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company’s segments include Consumer, Pharmaceutical and Medical Devices. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women’s health and wound care markets.
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.